News

Enobia develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Goldman, Sachs & Co. acted as financial advisor to Alexion. Ropes and Gray LLP acted

The financial details of the agreement have not been disclosed. The product is based on the Gibson Assembly method. Gibson Assembly uses a one-step, isothermal approach to enable

Prismic has also secured Scarista’s exclusive license from Amarin Neuroscience to develop, market, and out-license patents covering highly purified forms of omega-3 fatty acids for the treatment of

Based on this review classification, the FDA has issued an action date for the NDA of 5 June 2012 under the Prescription Drug User Fee Act (PDUFA). Salix

Under the agreement, the cross-royalty rates were reduced and commercial rights for certain territories were changed. Sobi will have commercial rights in Europe, Russia, Turkey and certain countries

Liposomal Grb-2 is indicated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

Mylan has acquired the abbreviated new drug application (ANDA) of the generic version of Valeant’s BenzaClin, Clindamycin Phosphate / Benzoyl Peroxide Gel. Mylan also has purchased a license

Vorapaxar, an investigational oral Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist, is being developed for the prevention of thrombosis, thereby reducing cardiovascular death (CVD). TRA-2P study demonstrated

The approval is backed by results from a randomized withdrawal study designed to assess the efficacy of Vyvanse in adults aged 18 to 55 years who were receiving